Dilip Singh
Neurology · Augusta, GANPI 1265886287
Payments from drug & device makers
Across 49 payments — averaging $24.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$195
- Stryker$146
- Amgen$117
- AstraZeneca$100
- UCB, Inc.$99
- Tanabe Pharma America, Inc.$71
- plus $453 from 15 others
What the payments were for
- Food & beverage$1,182100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 11 | $195 |
| Stryker | 1 | $146 |
| Amgen | 4 | $117 |
| AstraZeneca | 5 | $100 |
| UCB, Inc. | 4 | $99 |
| Tanabe Pharma America, Inc. | 3 | $71 |
| Pfizer | 3 | $69 |
| SK Life Science, Inc. | 2 | $66 |
| Jazz Pharmaceuticals Inc. | 3 | $63 |
| Ipsen Biopharmaceuticals, Inc | 2 | $42 |
| Lundbeck LLC | 1 | $32 |
| Argenx US, Inc. | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Greenwich Biosciences, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Chiesi USA, Inc. | 1 | $14 |
| Octapharma USA, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Natus Medical Incorporated | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TREVO$146
How this compares
$1,182 in reported general payments places this provider in the 45th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 11 | $7,642 |
| Lacosamide | 12 | $722 |
| Donepezil Hcl | 13 | $574 |
| Lamotrigine | 12 | $342 |
| Gabapentin | 11 | $300 |
| Atorvastatin Calcium | 17 | $172 |
| Amitriptyline Hcl | 17 | $163 |
Paid to pharmacies, not to this prescriber.
Other neurology in Augusta
- John MorganAugusta$1.3M
- Alexis ShaeferAugusta$279K
- Askiel BrunoAugusta$275K
- Jerry PruittAugusta$121K
- Bryan HoAugusta$97K
- Debra Moore-HillAugusta$88K
- Kapil SethiAugusta$55K
- Jonathan LissColumbus$25M
- Marshall NashDecatur$13.6M
- James LahAtlanta$6.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.